Trial Profile
A Follow-up Study to Evaluate the Long-term Persistence of GSK Biologicals' Candidate CMV Vaccine Administered to Male Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Cytomegalovirus glycoprotein vaccine (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 05 Jun 2017 New trial record